THE LATEST

NEWS & EVENTS

  • Sort By:
Oct 19, 2018

Efficacy and safety of ustekinumab, an IL-12 and IL-23 inhibitor, in patients with active systemic lupus erythematosus: results of a multicentre, double-blind, phase 2, randomised, controlled study

Ustekinumab is a monoclonal antibody targeting interleukin (IL)-12 and IL-23 and is approved for the treatment of plaque psoriasis, psoriatic arthritis, and Crohn’s disease. IL-12 and IL-23 have been implicated in systemic lupus erythematosus. We aimed to assess the efficacy and safety of ustekinumab for the treatment of systemic lupus erythematosus in patients with moderate-to-severe disease activity despite conventional treatment.

Oct 19, 2018

First Latin American clinical practice guidelines for the treatment of systemic lupus erythematosus: Latin American Group for the Study of Lupus (GLADEL, Grupo Latino Americano de Estudio del Lupus)–Pan-American League of Associations of Rheumatology (PANLAR)

Systemic lupus erythematosus (SLE) is a complex multisystemic autoimmune disease resulting, oftentimes, in irreversible damage, diminished quality of life and reduced life expectancy.1–3 Genetic and environmental factors play important roles in its pathogenesis.4–8 Disease manifestations and severity vary according to the patients’ racial/ethnic background and socioeconomic status (SES).

Oct 19, 2018

Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial

Systemic lupus erythematosus is a multisystem, chronic autoimmune disease characterised by the presence of antibodies directed at self-antigens, and broad immune dysregulation. It is believed that abnormalities of both the innate and adaptive arms of the immune system, interconnected by a positive feedback loop, contribute to disease pathogenesis.

Oct 19, 2018

The British Society for Rheumatology guideline for the management of systemic lupus erythematosus in adults

SLE (or lupus for short) is a multisystem, autoimmune disease, involving complex pathogenetic mechanisms that can present at any age. It most commonly presents in women in the reproductive age group, although lupus is increasingly recognized after the age of 40 years, particularly in Europeans…

Mar 12, 2018

Dr. John Hanly receives 2018 CRA Distinguished Investigator Award

John Hanly, born in Ireland, obtained his medical degree in 1978 at the National University of Ireland in Cork. Following post-graduate training in Internal Medicine and Rheumatology, he relocated to Canada in 1984 for fellowship training in Clinical Immunology and Rheumatology at the University of Toronto. Additional research training followed at McMaster University and Cornell University, New York City.

Next
1 of 3